P067 - Predictors of resistance to abiraterone acetate (AA) or enzalutamide (ENZ) in patients with metastatic castration-resistant prostate cancer (mCRPC) in the post-docetaxel setting
Publication date: November 2019Source: European Urology Supplements, Volume 18, Issue 11Author(s): T. Omrcen, D. Eterovic, E. Vrdoljak
Source: European Urology Supplements - Category: Urology & Nephrology Source Type: research
More News: Abiraterone Acetate | Cancer | Cancer & Oncology | Docetaxel | Prostate Cancer | Taxotere | Urology & Nephrology